Anidulafungin injection bulk supplier for pharma manufacturers

Anidulafungin Injection 50 mg/vial Suppliers & Bulk Manufacturers

Available Forms: Intravenous (IV) Powder

Available Strengths: 50 mg/vial

Reference Brands: Eraxis(US)

Anidulafungin inhibits fungal β-glucan synthase, disrupting cell wall synthesis and leading to fungal cell death. It offers broad-spectrum activity against invasive Candida and Aspergillus infections, with rapid onset, minimal toxicity, and high efficacy. Its safety profile and effectiveness make it essential for treating life-threatening fungal diseases.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Anidulafungin IV powder is approved in the EU and US for treating invasive fungal infections. In the EU, Pfizer’s Eraxis is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and high manufacturing standards. In the US, FDA approval is based on comprehensive clinical data, biosimilarity assessments, and continuous pharmacovigilance. Both regions require detailed regulatory dossiers for initial approval and ongoing safety monitoring. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz. We support efficient market access for anidulafungin IV formulations, ensuring adherence to European and American standards for safe, effective antifungal therapy.

Anidulafungin Injection — third party manufacturing & bulk supply

Anidulafungin Injection 50 mg/vial is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Anidulafungin Injection is supplied as Intravenous (IV) Powder — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Anidulafungin Injection listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Anidulafungin Injection →

Back to Listing

Frequently Asked Questions

Anidulafungin injection is listed as Intravenous (IV) Powder in 50 mg/vial. Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Anidulafungin injection is referenced against Eraxis(US). Reference brands are shown for identification only and remain the property of their respective trademark owners.